Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Has essential hypertension and 24-hour mean systolic blood pressure greater than or equal to 140 mm Hg and less than or equal to 180 mm Hg.~2. Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study~3. Has clinical laboratory evaluations within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator.~4. Is willing to discontinue current antihypertensive medications.~Exclusion Criteria:~1. Has sitting trough clinic diastolic blood pressure greater than 119 mm Hg.~2. Has a baseline 24 hour ambulatory blood pressure monitoring reading of insufficient quality.~3. The subject is hypersensitive to angiotensin II receptor blockers or calcium channel blockers.~4. Has a recent history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack.~5. Has clinically significant cardiac conduction defects.~6. Has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease.~7. Has secondary hypertension of any etiology~8. Is non-compliant with study medication during placebo run-in period.~9. Has severe renal dysfunction or disease.~10. Has known or suspected unilateral or bilateral renal artery stenosis.~11. Has a history of drug abuse or a history of alcohol abuse within the past 2 years.~12. Has a previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug.~13. Has type 1 or poorly controlled type 2 diabetes mellitus.~14. Has hyperkalemia as defined by the central laboratory normal reference range,~15. Has an alanine aminotransferase level of greater than 2.5 times the upper limit of normal, active liver disease or jaundice.~16. Has an upper arm circumference less than 24 cm or greater than 42 cm.~17. Works night (3rd) shift.~18. Currently participating in another investigational study or has participated in an investigational study within 30 days prior to randomization.~19. Has any other serious disease or condition that would compromise subject safety or make it difficult to successfully manage and follow the subject according to the protocol.~20. Has been randomized in a previous TAK-491 study.~21. Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azilsartan Medoxomil 40 mg QD and Amlodipine 5 mg QD (Type: EXPERIMENTAL): None
- Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD (Type: EXPERIMENTAL): None
- Amlodipine 5 mg QD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete